胎盘生长因子及相关研究

摘要

Current novel antiangiogenic strategies with complementary mechanisms require to maximize efficacy of angiogenesis inhibitors and minimize the drug resistance. Study found the mechanisms of anti-placental growth factor antihody( αPlGF ), which regulates the angiogenic switch in disease. without affecting healthy tissues. With the clinical application of tumor angiogenesis inhibitors , placental growth factor(PlGF ) ,as a member of the VEGF family,has gradually become a new anti-angiogenic target. Here is to illustrate the PICF and it ' s related ligands ' functions from the aspects of PlGF's strurture , receptor and antibody , and elaborates its relations to the correlative diseases. PIGF and related ligands provide a new method for the disease forecast and treatment.%当前依赖互补机制的抗血管生成新疗法要求最大限度地增强血管生成抑制因子的效果,并最小限度地发生耐药性.研究发现抗胎盘生长因子抗体(aPlGF)参与调控发病部位的血管生成,而不影响健康组织.随着肿瘤血管生成抑制剂的临床应用,PlGF作为血管内皮生长因子家族中的一员,渐渐成为抗血管生成的新的靶标.现从PlGF的结构、受体、抗体等方面阐述PlGF及相关配体功能,PlGF与相关疾病的关系,为疾病的预测和治疗提供新的方法.